Format

Send to

Choose Destination
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S1-10. doi: 10.1517/14728222.2011.645806. Epub 2012 Mar 23.

NF-κB as a target for pancreatic cancer therapy.

Author information

1
Digestive Molecular Clinical Oncology Research Unit , Section of Medical Oncology, Department of Medicine, University of Verona, Verona, Italy.

Abstract

INTRODUCTION:

Pancreatic cancer is the fourth leading cause of adult cancer mortality in the USA. It represents one of the greatest challenges in cancer treatment. The NF-κB transcriptional factors are constitutively activated in the majority of pancreatic cancers and are involved in the regulation of numerous aspects of tumor development and progression. NF-κB and the signaling cascades that regulate its activity have thus become attractive targets for novel therapeutic approaches for pancreatic cancer.

AREAS COVERED:

This review describes and discusses the most important advances in the comprehension of the complex molecular biology of NF-κB, as well as the development of novel NF-κB-targeting strategies for the treatment of pancreatic cancer.

EXPERT OPINION:

Although the inhibition of NF-κB, especially when combined with more classic chemotherapeutic drugs, could be a promising therapeutic strategy, direct targeting NF-κB still faces important challenges. In the future, targeting nonredundant cytosolic mediators of the activation of NF-κB - such as TNF receptor associated factor family member-associated NF-κB activator -binding kinase 1 (TBK1) and TGF-beta activated kinase 1 (TAK1) - could represent a better approach to inhibit key processes in pancreatic tumor cells and make a difference for this devastating disease.

PMID:
22443181
DOI:
10.1517/14728222.2011.645806
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center